What Institute for Clinical Pharmacodynamics does

The Institute for Clinical Pharmacodynamics (ICPD) is a privately held contract research organization founded in 2004 and headquartered in Schenectady, New York, with a secondary office in Buffalo, NY. The company specializes in pharmacokinetic-pharmacodynamic (PK-PD) translational medicine for antimicrobial, antifungal, antiviral, and biologic drug development, operating as an integrated 'benchtop-to-bedside' service provider. ICPD combines in-house wet-lab capabilities — including LC/MS-MS analytical assays, One-Compartment Chemostat and Hollow Fiber in vitro infection models, and in vivo PK-PD infection models — with computational services such as Monte Carlo simulation, population PK-PD modeling, and joint preclinical-clinical Bayesian PK-PD model development.

The company's offering is delivered as a suite of contracted professional services to pharmaceutical and biotechnology drug developers, with pricing not publicly disclosed. ICPD generates revenue through direct B2B engagements, supplemented by government contracts (most recently an August 2024 award from the National Institute of Allergy and Infectious Diseases). Its go-to-market relies heavily on scientific credibility, evidenced by 1200+ peer-reviewed publications, 2500+ conference presentations, 250+ government workshop and advisory panel participations, and leadership's 25+ years of journal editorship. The organization also operates a two-year Research Fellowship Program that trains post-graduate scientists, functioning as both a talent pipeline and an inbound marketing channel.

Name

Institute for Clinical Pharmacodynamics

Legal name

Institute for Clinical Pharmacodynamics, Inc.

Website

https://icpd.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

ICPD is a privately held contract research organization that provides integrated PK-PD translational medicine services — modeling, simulation, and laboratory work — to pharmaceutical and biotechnology companies developing antimicrobials, antifungals, antivirals, and biologics.

Ownership category

akta.pro rank

Product category

Translational Pharmacokinetic-Pharmacodynamic Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Pharmacology & Pharmacometrics (Modeling & Simulation) (HLAIALAG)

akta.pro secondary industries

DMPK / ADME & Bioanalysis (HLAGAFAC), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Pharmacokinetic pharmacodynamic modeling
• Antimicrobial drug development
• Translational medicine services
• Contract research organization
• Clinical pharmacodynamics research

Headquarters

HQ city

Schenectady

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: ICPD provides specialized PK-PD translational medicine services to pharmaceutical and biotechnology companies developing antimicrobials, antifungals, antivirals, and biologics. Services include consulting, study design, analytical testing, and regulatory support under contract.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

ICPD provides contract research services in translational medicine for antimicrobial, antifungal, antiviral, and biologic drug development. Its work integrates preclinical and clinical pharmacokinetic-pharmacodynamic (PK-PD) data through modeling, simulation, and laboratory testing to determine optimal dose, interval, and duration for investigational drugs. Engagements span dose regimen selection, susceptibility breakpoint decisions, go-no-go assessments, and regulatory support for pharmaceutical and biotechnology clients.

Product overview

ICPD offers a comprehensive suite of translational medicine services for antimicrobial drug development, centered on pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation. The portfolio includes Monte Carlo simulation, population PK-PD model development, analytical drug assays (Biological, Chemical LC/MS-MS, Protein Binding), in vitro screening, in vitro infection models (One-Compartment Chemostat and Hollow Fiber), in vivo PK-PD infection models, and joint pre-clinical/clinical Bayesian modeling. Services support dose regimen selection, susceptibility breakpoint decisions, and go-no-go decisions. The company also operates a two-year Research Fellowship Program for post-graduate training. The offering functions as a unified service portfolio rather than a software platform, delivered through their own equipped laboratories with in vitro and in vivo capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• PK-PD Modeling and Simulation Services Pharmacokinetic-pharmacodynamic modeling and simulation services that integrate preclinical and clinical data through PK-PD modeling, Monte Carlo simulation, population PK-PD analyses, and joint preclinical/clinical Bayesian model development to support dose selection, susceptibility breakpoint decisions, and dosing guideline development for pharmaceutical and biotechnology sponsors developing antimicrobial, antifungal, antiviral, and biologic agents.
• Analytical Drug Assay Services
• In Vitro Screening and Infection Model Services
• In Vivo PK-PD Infection Model Services
• Two-Year Research Fellowship Program

Quantifiable outcome

• 9 out of 10 new antibiotics in the last decade have been touched by ICPD's translational medicine work.
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• National Institute of Allergy and Infectious Diseases (NIAID)coreStrategic or Co-development Partner · 1 August 2024ICPD won a contract with NIAID in August 2024. As part of this engagement, ICPD made its Conflict of Interest (COI) policy publicly available to reinforce transparency and trust when working with government partners. The partnership underscores ICPD's role as a trusted translational science collaborator for federal health agencies.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Certara: Certara is the largest dedicated pharmacometrics and PK-PD modeling & simulation company, offering software (Phoenix, Pirana) and services to pharma and biotech sponsors — directly competing with ICPD's core PK-PD modeling and regulatory-submission support offering.
• Simulations Plus: Simulations Plus provides PK/PD, physiologically-based PK (PBPK), and quantitative systems pharmacology modeling software and services — including the Lixoft acquisition — competing with ICPD in the same PK-PD modeling and simulation space.
• Metrum Research Group: Metrum Research Group is a specialized pharmacometrics and PK-PD consulting CRO providing population PK, exposure-response, and model-informed drug development services to pharma — closely aligned with ICPD's translational PK-PD service portfolio.
• Rosa & Co. Rosa & Co. delivers model-informed drug development, PK/PD, and systems pharmacology consulting for pharma and biotech sponsors — a specialized competitor to ICPD in mechanism-based PK-PD modeling and translational medicine services.

Broad incumbents

• ICON plc: ICON is a large global CRO providing clinical pharmacology, PK/PD, and regulatory services across therapeutic areas — competing with ICPD for outsourced antimicrobial and broader pharmacometrics work at big pharma sponsors.
• Eurofins Scientific: Eurofins is a global bioanalytical and CRO services provider with LC/MS-MS and PK capabilities, offering scaled alternatives to ICPD's analytical drug assay and bioanalytical PK-PD work.
• Labcorp Drug Development: Labcorp Drug Development (including the former Covance) is a global CRO offering bioanalytical, PK/PD, and clinical pharmacology services, providing a one-stop alternative to ICPD's specialized antimicrobial PK-PD services.
• Charles River Laboratories: Charles River Laboratories is a large, full-service CRO offering preclinical, bioanalytical, and PK/PD services as part of a much broader portfolio — competes with ICPD for PK/PD and antimicrobial development engagements at larger pharma sponsors.

Emerging players

• QPS Holdings: QPS Holdings is a CRO with dedicated early-phase clinical and bioanalytical services including PK/PD and DMPK capabilities, partially overlapping ICPD's laboratory and PK-PD service mix for preclinical and translational antimicrobial work.

Others

• National Institute of Allergy and Infectious Diseases (NIAID) extramural pharmacology contractors: Academic medical centers and government-affiliated pharmacology cores (e.g., University at Buffalo, NIH-funded contract research units) compete for the same NIAID translational science contracts and government workshop influence that ICPD leverages.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/institute-for-clinical-pharmacodynamics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institute for Clinical Pharmacodynamics